How Tesamorelin Cuts Visceral Fat Without Raising Blood Sugar

Most TRT users who chase that last pocket of lower-belly fat get told the same thing: cut harder, run more, wait it out. It rarely works. Visceral adipose tissue is metabolically different from the subcutaneous fat you can pinch, and on testosterone, with shifted lipids and creeping insulin resistance, it stops responding to the levers that worked at 25.

Tesamorelin is the only peptide with FDA Phase III data showing a direct, selective hit on that compartment. The interesting part is not the headline 15% number every vendor blog repeats. It is the sub-analysis nobody quotes: men with metabolic syndrome (high triglycerides, high HOMA-IR, central adiposity) responded almost twice as hard as the average. That phenotype maps neatly onto the typical TRT user with stubborn VAT.

This guide covers what the drug actually does, what your bloodwork should look like at week 4, 12, and 26, the decision tree for whether to keep going, and how it stacks up against CJC-1295, ipamorelin, MK-677, and retatrutide.

What tesamorelin actually is

Tesamorelin is a 44-amino-acid synthetic analog of human growth hormone-releasing hormone (GHRH). The trick is a single structural tweak: a trans-3-hexenoic acid cap on the N-terminus. That cap sterically blocks dipeptidyl peptidase-4 (DPP-4), the enzyme that otherwise chews the first two residues off native GHRH within about seven minutes. With DPP-4 disabled, the molecule survives long enough to reach the pituitary GHRH receptor and trigger a real GH pulse.

The drug's own half-life is short, around 26 to 38 minutes. That sounds like a problem until you remember that GHRH is supposed to pulse. Tesamorelin produces an endogenous, physiological GH pulse. Your own pituitary fires, your own negative feedback loop (IGF-1 to somatostatin) stays intact, and your overnight GH profile looks almost normal. That is the structural reason it behaves so differently from exogenous HGH or CJC-1295 DAC, both of which create a continuous supraphysiologic GH and IGF-1 bleed and pay for it with insulin resistance.

The FDA approved tesamorelin in November 2010 under the brand Egrifta, indicated for HIV-associated lipodystrophy. A 2024 reformulation (Egrifta SV) delivers the same biological dose at 1.4 mg subcutaneous instead of 2 mg, with simpler reconstitution. Both forms are tesamorelin. Off-label use in non-HIV bodybuilders and TRT patients with visceral fat leverages the same mechanism, and the Stanley 2014 JAMA trial (PMID 25038357) already extended the data into a non-lipodystrophy context by showing the same VAT and liver fat effects in HIV patients without classic lipodystrophy.

The pulsatile-versus-continuous distinction is not academic. It is the entire reason you can run tesamorelin alongside testosterone and not see your fasting glucose drift the way MK-677 or 2 IU of HGH would push it.

The metabolic syndrome responder data nobody talks about

Every tesamorelin write-up quotes Falutz 2007 (NEJM, PMID 18057338): 412 HIV patients, 2 mg/day, 26 weeks, VAT down 15.2% versus a 5% rise in placebo. Fine. The interesting work is the Mangili 2015 sub-analysis (PLOS ONE, PMID 26457580), which pooled the two Phase III trials (combined enrolment 806 patients) and asked who responded best.

Three predictors fell out of the regression. Metabolic syndrome by NCEP criteria, baseline triglycerides above 1.7 mmol/L (about 150 mg/dL), and white race. The first two are the ones that matter for TRT users.

In the metabolic syndrome subgroup, VAT changed by -24.4 cm² on tesamorelin versus +8.6 cm² on placebo. In the high-triglyceride subgroup, -28.4 cm² versus +2.3 cm². Compare those to the overall pooled mean of around -15 cm² and you get the point. The men with the worst metabolic profile at baseline got nearly double the average VAT loss.

That is the phenotype to remember. Low SHBG, triglycerides over 150 mg/dL, waist over 102 cm, fasting insulin above 10, central adiposity that does not budge on a normal cut. That is half the men running TRT in their forties. It is also exactly the group the Mangili data identifies as the biggest tesamorelin responders.

The flip side is just as important. A lean, insulin-sensitive 28-year-old bodybuilder with TG at 80 and single-digit body fat is not going to see a 28 cm² VAT loss. There is not enough metabolically active visceral fat left to mobilise. Mechanism does not care about hype.

For practical purposes: if your bloodwork shows a metabolic syndrome pattern, tesamorelin is mechanistically the right tool. If your bloodwork is clean and your problem is subcutaneous fat distribution rather than visceral, you are buying the wrong drug.

Your bloodwork on tesamorelin week by week

Here is what to draw, when to draw it, and what the numbers should look like.

Baseline (before first injection)

Pull IGF-1, fasting glucose, HbA1c, fasting insulin, a full lipid panel (LDL, HDL, triglycerides, total cholesterol, ideally apoB), ALT and AST, TSH and free T4, and CRP. If you have access, get a DEXA with VAT score. Without a baseline number you cannot tell drift from noise.

Week 1 to 2: IGF-1 spike

Stanley 2011 (JCEM, PMID 20943777) gave 2 mg/day to healthy men for 2 weeks. IGF-1 rose 181 ± 22 mcg/L (about +47% from baseline) by day 14, and insulin-stimulated glucose uptake on a clamp was unchanged (p=0.61). Translation: the GH pulse hits fast, IGF-1 climbs immediately, and insulin sensitivity does not move.

You do not need to draw at week 2. Just expect your IGF-1 is now somewhere between 90 and 180 ng/mL higher than baseline.

Week 4: first IGF-1 check (if baseline was high)

If your baseline IGF-1 was above 250 ng/mL, draw a week 4 IGF-1 to see whether you are heading past the upper-normal range. For most TRT users in their thirties and forties, the target is to keep IGF-1 below about 270 to 300 ng/mL (under 2 SDS above age-adjusted normal). Above 3 SDS, the FDA label calls for discontinuation. Around 47% of Phase III patients hit >2 SDS by week 26 and 36% hit >3 SDS, so this is not theoretical.

If baseline IGF-1 was already in the 150 to 200 range, wait until week 12.

Week 12: full panel

Repeat IGF-1, fasting glucose, HbA1c, fasting insulin, lipids, ALT, AST.

In the Falutz responder cohort (Stanley CID 2012, PMID 22495074), at week 12 to 26:

• Fasting glucose: +1 mg/dL in responders, +5 mg/dL in non-responders (the gap matters)
• HbA1c: +0.1% in responders, +0.3% in non-responders
• Fasting insulin: -1.1 µIU/mL in responders, +5.7 in non-responders (p=0.011)
• Triglycerides: -50 mg/dL in responders by week 26
• Total cholesterol: -8 mg/dL in responders

The responder versus non-responder split is the critical piece. Responders (those who drop at least 8% VAT by week 26) preserve glucose homeostasis. Non-responders drift up on glucose and HbA1c and should be discontinued before they do real metabolic damage.

Week 26: efficacy check

DEXA or waist circumference. If your VAT score has not dropped meaningfully, stop. Continuing in the non-responder profile means buying glucose drift with no body composition return.

Liver fat (if relevant)

Stanley 2019 (Lancet HIV, PMID 31611038) ran tesamorelin at 2 mg/day for 12 months in 61 HIV patients with NAFLD. Hepatic fat fraction dropped 37% in relative terms (-4.1% absolute). 35% of tesamorelin patients normalised liver fat to under 5% versus 4% on placebo (p=0.0069). If you have a fatty liver diagnosis from a bodybuilding history of oral 17-alpha-alkylated compounds, this is the angle nobody covers. Track ALT, AST, and consider a FibroScan or MRI-PDFF at baseline and 12 months.

Does tesamorelin raise blood sugar on TRT? A decision tree

This is the question that surfaces on every forum thread. The short answer is "almost never in responders, often in non-responders." Here is how to tell which side you are on, and when to pull the plug.

Step 1: Baseline. If your starting HbA1c is already ≥5.7% (pre-diabetic) or your fasting glucose is >100 mg/dL on two separate draws, fix the underlying metabolic picture first. Add metformin if your doctor agrees, tighten carbs, and consider a low-dose GLP-1 first. Tesamorelin works well in metabolic syndrome but assumes you are not already over the diabetic line.

Step 2: First 4 weeks. Expect transient effects. Stanley 2014 documented a small fasting glucose bump at week 2 that fully resolved by 6 months. If your glucose is up 5 to 8 mg/dL at the first repeat draw, do not panic. That is the early adaptation.

Step 3: Week 12 decision point. Pull fasting glucose, HbA1c, and fasting insulin. Run the numbers:

• HbA1c up less than 0.2% from baseline: continue.
• HbA1c up 0.2 to 0.4%: hold the dose, tighten diet, recheck at week 16.
• HbA1c up >0.4% or fasting glucose >110 mg/dL two readings in a row: reduce to 1 mg/day or pause.

Step 4: Week 26 hard stop. HbA1c ≥6.5% is the FDA's line. Pooled Phase III data showed a hazard ratio of 3.3 (95% CI 1.4 to 9.6) for crossing into diabetes versus placebo, with 5% of EGRIFTA-treated patients hitting that line versus 1% on placebo. Small but real. Cross it and you stop.

Step 5: VAT efficacy gate. If you cannot show ≥8% VAT reduction at week 26 (the Stanley 2012 responder threshold), discontinue regardless of glucose. Non-responders pay metabolic costs for nothing.

The decision tree assumes monthly monitoring. If you are running tesamorelin without baseline labs and quarterly bloodwork, you are guessing.

Tesamorelin versus CJC-1295, ipamorelin, MK-677, and retatrutide for belly fat on TRT

This is where most "GH peptide" content collapses into vibes. Here is the actual evidence table.

A few things to pull out of that table.

Tesamorelin is the only GH-axis compound with Phase III VAT outcome data. Everything else on the GH side (CJC, ipamorelin, MK-677) is mechanism plus extrapolation. That does not make them useless, but it does make their VAT claims weaker than tesamorelin's.

MK-677 raises fasting glucose 25 to 27% in 4 weeks (Chapman 1996, PMID 8954023). That is the central reason it is the wrong tool on cycle, especially if you are running 19-nors, EQ, or any other compound that worsens lipids and insulin sensitivity. Cheap, oral, and metabolically expensive.

GLP-1s work on a different axis. Semaglutide and tirzepatide drive VAT loss via caloric deficit, which is why they also take 8 to 11% lean mass with them in body composition substudies. Tesamorelin drives VAT loss via GH-mediated lipolysis while sparing or increasing lean mass. The two stack cleanly. For a TRT user with metabolic syndrome, low-dose semaglutide plus tesamorelin hits both the energy balance and the visceral compartment without the insulin resistance penalty of MK-677 or HGH.

Retatrutide is the wild card. TRIUMPH Phase II showed -48% VAT at 12 mg/week, which is more than tesamorelin produces. But it is research-grade only and the lean mass preservation story is still being written. If you want maximum VAT removal and accept investigational risk, retatrutide is the strongest option. If you want Phase III certainty and a clean glucose profile, tesamorelin.

CJC plus ipamorelin is the popular "tesamorelin alternative" for cost reasons. The mechanism is plausible (a GHRH-analog pulse stacked with a GHRP), but there is no VAT outcome trial. Paying $60/month buys you mechanism plus hope. Paying $300/month for tesamorelin buys you Phase III certainty.

Dosing: 1 mg versus 2 mg, when to titrate, when to stop

The original Egrifta dose is 2 mg subcutaneous daily, reconstituted from two 1 mg vials with 2.2 mL sterile water each. Egrifta SV simplified that to 1.4 mg from a single 2 mg vial reconstituted with 0.5 mL sterile water. The two doses are bioequivalent. For practical purposes, 1.4 mg SV = 2 mg Egrifta.

The bodybuilder ramp:

• Weeks 1 to 4: 1 mg SC nightly. Matches the Clemmons 2017 low-dose arm (PMID 28617838), which showed real IGF-1 elevation (+33 ng/mL) at half the side effect rate of 2 mg.
• Weeks 5 to 26: 1.4 mg or 2 mg SC nightly. This is the FDA-tested efficacy dose.
• Week 26: reassess with bloodwork and DEXA. If responder, continue. If non-responder, stop.

Reconstitution math (Egrifta SV): one 2 mg vial plus 0.5 mL bacteriostatic water = 4 mg/mL solution. 1.4 mg = 0.35 mL. The 1 mg starter dose = 0.25 mL. Use a 29 to 31 gauge insulin syringe, 5/16 inch.

Injection technique is subcutaneous in the abdomen, two inches from the navel, rotating sites two inches apart. Avoid the belt line and any scar tissue.

Timing: bedtime on an empty stomach. Eat your last meal at least 2 hours before. The rationale is mechanistic, not from a head-to-head trial. GH secretion is overnight-weighted, and elevated insulin or glucose blunts the somatotrope response.

Duration: the FDA pivotal data extends to 52 weeks with sustained VAT reduction (Falutz 2008/2010 extension). Beyond 52 weeks, there are no prospective RCT data. Indefinite use is a personal risk calculation, not an evidence-based protocol.

What happens when you stop

The Falutz 2010 JAIDS extension (PMID 20101189) is the cleanest rebound dataset. Patients re-randomised from tesamorelin to placebo at week 26 lost essentially all their VAT gains within the next 26 weeks. The drug does not fix the underlying metabolic milieu, it suppresses the visible symptom while you inject. Stop, and the visceral fat comes back.

That leaves three bridging options, none with published RCT support:

1. Maintenance dose drop. 1 mg every other day or 1 mg daily. No published data on this protocol, extrapolated from the placebo-arm rebound timing. Worth trying if cost is the constraint.

2. CJC-1295 plus ipamorelin transition. Substitute CJC-1295 (no DAC) 100 mcg plus ipamorelin 100 mcg pre-bed during off-cycles to maintain pulsatile GH stimulation at lower cost. No head-to-head VAT trial against tesamorelin, but the mechanism is reasonable.

3. Lifestyle anchoring. Aerobic conditioning, protein and leucine sufficiency, fasted training, and a tight sleep window protect against rapid VAT rebound. But the Falutz data is brutal: pharmacological discontinuation alone reverses VAT regardless of lifestyle. Lifestyle is necessary, not sufficient.

If you needed tesamorelin to clear visceral fat, you almost certainly need a maintenance strategy. Plan for that before you start.

A VitalMetrics monitoring protocol

Here is the consolidated monitoring schedule:

• Baseline: IGF-1, fasting glucose, HbA1c, fasting insulin, full lipid panel, ALT, AST, TSH, free T4, CRP, DEXA with VAT score if available.
• Week 4: IGF-1 only, and only if baseline IGF-1 was >250 ng/mL.
• Week 12: IGF-1, fasting glucose, HbA1c, fasting insulin, lipids, ALT, AST.
• Week 26: Full repeat panel plus DEXA. This is the efficacy and continuation decision point.
• Every 12 weeks after 26: IGF-1, fasting glucose, HbA1c, ALT.

Read your IGF-1 at the trough (12 to 16 hours post-injection, fasted morning), not at peak. The drug's plasma half-life is short, so trough IGF-1 reflects integrated GH exposure and is the most reproducible read.

Pair this with the rest of a TRT bloodwork rhythm. See our complete guide to bloodwork for bodybuilders for the broader cadence, and blood test timing on TRT for draw timing details that translate directly to peptide monitoring.

If you are running tesamorelin alongside a GLP-1, add lipase and amylase to the baseline and week 12 draws. If you are stacking with exogenous HGH (please reconsider that combination), the glucose monitoring cadence needs to tighten further. See our GH and insulin resistance article for the mechanism and the MK-677 blood sugar guide for the cautionary case study.

Key takeaways

• Tesamorelin is the only peptide with FDA Phase III data for visceral fat reduction. Expect 15 to 18% VAT loss at 26 weeks in responders.
• The Mangili 2015 sub-analysis identifies metabolic syndrome and TG >150 mg/dL as the strongest response predictors. TRT users with that phenotype are the biggest responders.
• Glucose neutrality is the headline difference versus HGH and MK-677. Insulin-stimulated glucose uptake unchanged on a clamp (p=0.61). HbA1c stable in responders.
• Pull IGF-1, fasting glucose, HbA1c, lipids, and ALT at baseline. Recheck at week 12 and week 26.
• Hard stop rules: HbA1c ≥6.5%, IGF-1 persistently >3 SDS, or no measurable VAT reduction at week 26.
• 1 mg as a starter dose works (Clemmons 2017). Titrate to 1.4 or 2 mg.
• VAT rebounds fast after discontinuation. Plan a maintenance strategy before starting.
• Tesamorelin stacks cleanly with GLP-1s. It does not stack well with HGH or MK-677 (redundant GH stimulation, additive metabolic cost).
• This is off-label outside HIV lipodystrophy. Do not run it without baseline labs.

---

References

1. Falutz, J., Allas, S., Blot, K., Potvin, D., Kotler, D., Somero, M., Berger, D., Brown, S., Richmond, G., Fessel, J., Turner, R., & Grinspoon, S. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359-2370. PubMed

2. Falutz, J., Mamputu, J. C., Potvin, D., Moyle, G., Soulban, G., Loughrey, H., Marsolais, C., Turner, R., & Grinspoon, S. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. Journal of Clinical Endocrinology & Metabolism, 95(9), 4291-4304. PubMed

3. Falutz, J., Potvin, D., Mamputu, J. C., Assaad, H., Zoltowska, M., Michaud, S. E., Berger, D., Somero, M., Moyle, G., Brown, S., Martorell, C., Turner, R., & Grinspoon, S. (2010). Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. Journal of Acquired Immune Deficiency Syndromes, 53(3), 311-322. PubMed

4. Mangili, A., Falutz, J., Mamputu, J. C., Stepanians, M., & Hayward, B. (2015). Predictors of treatment response to tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat. PLOS ONE, 10(10), e0140358. PubMed

5. Stanley, T. L., Chen, C. Y., Branch, K. L., Makimura, H., & Grinspoon, S. K. (2011). Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. Journal of Clinical Endocrinology & Metabolism, 96(1), 150-158. PubMed

6. Stanley, T. L., Falutz, J., Mamputu, J. C., Soulban, G., Potvin, D., & Grinspoon, S. K. (2012). Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clinical Infectious Diseases, 54(11), 1642-1651. PubMed

7. Stanley, T. L., Feldpausch, M. N., Oh, J., Branch, K. L., Lee, H., Torriani, M., & Grinspoon, S. K. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: A randomized clinical trial. JAMA, 312(4), 380-389. PubMed

8. Stanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Zheng, I., Pan, C. S., Aepfelbacher, J., Buckless, C., Tsao, A., Kellogg, A., Branch, K., Lee, H., Liu, C. Y., Corey, K. E., Chung, R. T., Torriani, M., Kleiner, D. E., Hadigan, C. M., & Grinspoon, S. K. (2019). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre, placebo-controlled trial. Lancet HIV, 6(12), e821-e830. PubMed

9. Clemmons, D. R., Miller, S., & Mamputu, J. C. (2017). Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS One, 12(6), e0179538. PubMed

10. Chapman, I. M., Bach, M. A., Van Cauter, E., Farmer, M., Krupa, D., Taylor, A. M., Schilling, L. M., Cole, K. Y., Skiles, E. H., Pezzoli, S. S., Hartman, M. L., Veldhuis, J. D., Gormley, G. J., & Thorner, M. O. (1996). Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. Journal of Clinical Endocrinology & Metabolism, 81(12), 4249-4257. PubMed

11. Nass, R., Pezzoli, S. S., Oliveri, M. C., Patrie, J. T., Harrell, F. E. Jr., Clasey, J. L., Heymsfield, S. B., Bach, M. A., Vance, M. L., & Thorner, M. O. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: A randomized trial. Annals of Internal Medicine, 149(9), 601-611. PubMed

12. Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805. PubMed

13. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. PubMed

14. Jastreboff, A. M., Kaplan, L. M., Frias, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023). Triple-hormone-receptor agonist retatrutide for obesity. A phase 2 trial. New England Journal of Medicine, 389(6), 514-526. PubMed